Relmada Therapeutics Inc
NASDAQ:RLMD
Relmada Therapeutics Inc
Total Equity
Relmada Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
Total Equity
$9.5m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-4%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$81.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$18.5B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
3%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$86.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$52.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$26.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
36%
|
CAGR 10-Years
6%
|
|
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
See Also
What is Relmada Therapeutics Inc's Total Equity?
Total Equity
9.5m
USD
Based on the financial report for Sep 30, 2025, Relmada Therapeutics Inc's Total Equity amounts to 9.5m USD.
What is Relmada Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-4%
Over the last year, the Total Equity growth was -80%. The average annual Total Equity growth rates for Relmada Therapeutics Inc have been -62% over the past three years , -40% over the past five years , and -4% over the past ten years .
